N/A N=165 Passive Disinfection Cap Compliance Study
Infection, Hospital
Primary: Disinfecting Barrier Cap Compliance — 98.43 percentage of connector with compliance
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Community Central Line Infection Prevention Trial
Infection
Primary: Total Number of Central Line Associated Blood Stream Infections (CLABSI) — 113; 84; 123; 109 infections
Phase 3 N=95 Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
Central Line-Associated Bloodstream Infection
Primary: Percentage of Therapeutic Failures (Early or Late Failure) in Children and Adolescents With CLABSI Receiving Standard Care Plus Ethanol Lock Therapy (ELT) vs. Standard…
N/A N=60 Safe Critical Care: Testing Improvement Strategies
Central Line-associated Bloodstream Infection (CLABSI) · Ventilator Associated Pneumonia
Primary: CLABSI and VAP Rates — 1.84; 2.42; 2.24; 2.47 events/1000 device days — p=<.05
Phase 3 N=177 Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Bacterial Infection · Benign Neoplasm · Malignant Neoplasm
Primary: Central Line-associated Bloodstream Infections (CLABSI) Events During the At-risk Days — 5.44; 3.1 CLABSI per 1000 at-risk days.
Phase 2 N=20 t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection
Central Venous Catheter Thrombosis · Central Venous Catheter Associated Bloodstream Infection
Primary: Catheter-associated Venous Thrombosis — 3; 3 Participants
N/A N=119 Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT
Central Line Associated Bloodstream Infections (CLABSI) · Bone Marrow Transplant
Primary: Rate of Central Line Associated Bloodstream Infections (CLABSI) — 3.69; 4.37 CLABSI/1000 catheter-days
N/A N=149 Hub Cleansing to Prevent Hub Infection
Bacteremia
Primary: Number of Central Venous Catheter Hubs With Internal Contamination — 42; 18; 39; 14 contaminated hubs
Phase 2 N=41 Catheter Related - Gram Positive Bloodstream Infections
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
Phase 2 N=50 A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients
Stem Cell Transplant Complications
Primary: Number of Participants With Primary Blood Stream Infections — 1; 2 Participants
Phase 4 N=1,088 Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH)
Catheter-related Bloodstream Infection
Primary: The Number of Catheter Related Bloodstream Infections (BSI) /1000 Catheter Days in Both Arms — 4.74; 4.72 BSIs /1000 catheter days — p=0.05
N/A N=701 Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
End Stage Renal Disease (ESRD)
Primary: Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-Days — 0.28; 0.75 PBCs per 1,000 CVC-days
Phase 2 N=60 Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
Catheter-Associated Infections · Catheter-Related Infections
Primary: Number of Participants With Drug-Related Hypotension — 0 Participants
Phase 4 N=13 Antifungal Locks to Treat Fungal-related Central Line Infections
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…
N/A N=350 Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit
Cross Infection · Pneumonia, Ventilator-associated · Catheter-related Infections
Primary: Incidence of Nosocomial Infection — 15; 30 participants — p=0.049
N/A N=1,229 Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
End Stage Renal Disease (ESRD)
Primary: Positive Blood Cultures (PBCs) Per 1,000 Central Venous Catheter (CVC)-Days — 0.26; 0.59 PBCs per 1,000 CVC-days
Phase 4 N=434 Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System
Intraventricular Hemorrhage · Subarachnoid Hemorrhage
Primary: Number of Infections — 4; 5; 4; 5 Infections
N/A N=100 Capillary Leak Index as a Prognostic Indicator for Post-Operative Abdominal Sepsis in Critically Ill Patients
Intra-Abdominal Infections · Intestinal Obstruction · Appendicitis Acute
Primary: Number of Participants Who Died by Day 28 — 8; 23 Participants — p=0.001
N/A N=500 Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
N/A N=2,905,455 CLUSTER Trial for Outbreak Detection and Response
Cluster Detection
Primary: Cluster Size — 1.81; 1.41 outbreak cases after first signal
Phase 4 N=27 Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
Leukemia · Lymphoma · Blood Disorders
Primary: Length of Stay (LOS) in Those With 14 Confirmed Catheter Related Infection Cases — 124; 208 HOURS
N/A N=418 Targeted Infection Control in Long-term Care
Infection
Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05
N/A N=35 Comparing Peripherally Inserted Central Catheters to Long Peripheral Catheters in Pediatrics
Vascular Access Device Complications
Primary: Percent Eligible Patients That Agreed to Participate — 80 percentage of eligible patients agreed t
N/A N=212 Midlines and Thrombophlebitis
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants
N/A N=295 Study to Estimate the Point Prevalence of Peripheral Intravenous Catheter-related Complications in Brazil
Infusion Site Injury
Primary: Percentage of PIVCs Sites With at Least One Clinical or Mechanical Complication (PIVC-related Complications) — 10; 6; 7 percentage of PIVC sites
N/A N=217 Central Venous Access Study
Central Line Catheters
Primary: Adherence to Clinical Guidelines for Catheter Interventions and Management — 12; 0; 0; 11 # of catheter-related incidents
N/A N=338 A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients
End Stage Renal Failure on Dialysis · Complication of Dialysis · Blood Coagulation Disorders
Primary: Clotting of Extracorporeal Dialysis Circuit — 30; 33 Clotting events — p=0.79
N/A N=339,902 Active Bathing to Eliminate Infection (ABATE Infection) Trial
Healthcare Associated Infections · Methicillin Resistant Staphylococcus Aureus · Multi Drug Resistant Organisms
Primary: MRSA and VRE Clinical Cultures — 0.87; 0.79 Hazard Ratio (Intervention vs Baseline) — p=0.17
N/A N=3,723 Three-Chamber Bags Retrospective Study in Spain
Parenteral Nutrition · Blood Stream Infection
Primary: Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB) — 127; 106 Participants
N/A N=2,140 Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance
Methicillin-resistant Staphylococcus Aureus
Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026